vTv says CATT1 Phase III enrollment nearing completion; options granted
vTv Therapeutics says its Phase III CATT1 trial enrollment is nearing completion, with top-line data expected in 2027 and funding deemed sufficient. The company granted inducement stock options to a non-executive employee exercisable at $31.44, including a 2,500-option grant.